Surgical Robotics Technology
Microbot Medical Inc. a developer, manufacturer and distributer of the innovative LIBERTY® Endovascular Robotic System, announced that the Japanese Patent Office has granted the Company its first patent in Japan, covering the core LIBERTY® System technology, such as a compact robotic device for driving and manipulating movement of at least one elongate surgical tool. In addition to today’s news, the Company has also received patents in the U.S., China and Israel over the past 90 days.
The Company announced marketing clearance for the LIBERTY® System by the U.S. Food and Drug Administration (FDA) on September 8, 2025, and has accelerated its commercial launch plans as it targets an estimated 2.5 million peripheral endovascular procedures performed in the U.S., annually. As the Company evaluates other future global markets that have historically accepted FDA cleared devices, the successful implementation of its global IP strategy is expected to protect and allow it to monetize its innovative technology.
“Our initial focus is on the US market, however, certain markets such as Japan, represent attractive and strategically important markets for the LIBERTY® System,” commented Harel Gadot, Chairman, CEO & President. “Building on our recent FDA clearance of LIBERTY®, we are evaluating opportunities to expand into other global markets that have traditionally taken FDA clearance into consideration to potentially expedite local approval and adoption.”
Source: Microbot Medical
